Steven Coutre

Steven Coutre

UNVERIFIED PROFILE

Are you Steven Coutre?   Register this Author

Register author
Steven Coutre

Steven Coutre

Publications by authors named "Steven Coutre"

Are you Steven Coutre?   Register this Author

100Publications

3685Reads

8Profile Views

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

N Engl J Med 2019 08;381(5):432-443

From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1817073DOI Listing
August 2019

A one-two punch with VO KOs CLL.

Authors:
Steven Coutre

Blood 2019 Jun;133(26):2737-2738

Stanford University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2019-04-901116DOI Listing
June 2019

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

N Engl J Med 2018 12 1;379(26):2517-2528. Epub 2018 Dec 1.

From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); Stanford University School of Medicine, Stanford (S.C.), and the City of Hope Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1812836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325637PMC
December 2018

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.

Blood Adv 2018 08;2(15):1946-1956

Center for Primary Care and Outcomes Research/Center for Health Policy, Department of Medicine, Stanford University School of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017015461DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093732PMC
August 2018

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

J Clin Oncol 2018 07 1;36(19):1973-1980. Epub 2018 May 1.

Stephan Stilgenbauer and Johannes Bloehdorn, Ulm University, Ulm; Stephan Stilgenbauer, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; Barbara Eichhorst and Michael Hallek, Universitätsklinikum Köln, Köln; Johannes Schetelig, University Hospital, Technische Universität Dresden, Dresden; Clemens-Martin Wendtner, Klinikum Schwabing, Munich; Sebastian Böttcher, University Hospital of Schleswig-Holstein, Kiel, Germany; Peter Hillmen and Talha Munir, St James's University Hospital, Leeds; Anna Schuh, University of Oxford; Anna Schuh, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; John F. Seymour, Peter MacCallum Cancer Centre; John F. Seymour, University of Melbourne; Andrew W. Roberts, Royal Melbourne Hospital, Parkville, Victoria; Stephen P. Mulligan, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Steven Coutre, Stanford University Medical Center, Stanford, CA; Wojciech Jurczak, Jagiellonian University, Kraków, Poland; Sarit Assouline, McGill University, Montreal, Quebec, Canada; Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer Arzt, Su Young Kim, Maria Verdugo, and Gary Gordon, AbbVie, North Chicago, IL; Ahmed Hamed Salem, Ain Shams University, Cairo, Egypt; and William G. Wierda, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6840DOI Listing
July 2018

Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.

Br J Haematol 2018 01 18;180(1):164-166. Epub 2016 Aug 18.

Department of Medicine, Division of Oncology, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14302DOI Listing
January 2018

Evolving Frontline Treatment in Chronic Lymphocytic Leukemia.

Authors:
Steven E Coutre

Clin Adv Hematol Oncol 2016 May;14(5 Suppl 8):5-6

Stanford University Medical Center, Stanford, California.

View Article

Download full-text PDF

Source
May 2016

Discussion: Managing Risk When Using Idelalisib.

Clin Adv Hematol Oncol 2016 May;14(5 Suppl 8):13

Hematopoietic Stem Cell Transplantation Program, Swedish Cancer Institute, Seattle, Washington.

View Article

Download full-text PDF

Source
May 2016

A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

Br J Haematol 2016 Apr 4;173(2):253-9. Epub 2016 Apr 4.

Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13946DOI Listing
April 2016

Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.

Am J Surg Pathol 2015 Dec;39(12):1653-60

Departments of *Pathology ‡Medicine (Hematology), Stanford University School of Medicine, Stanford †Department of Pathology, University of California Davis, Sacramento, CA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/ajsp/2015/12000/Idelalisib_asso
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PAS.0000000000000525DOI Listing
December 2015

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

N Engl J Med 2015 Dec 6;373(25):2425-37. Epub 2015 Dec 6.

From the University of Texas MD Anderson Cancer Center, Houston (J.A.B.); Azienda Ospedaliera Niguarda Cà Granda (A.T.) and Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele (P.G.), Milan, and the Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara (G.G.) - all in Italy; Wilmot Cancer Institute, University of Rochester, Rochester, NY (P.M.B.); Medical University of Lodz and Copernicus Memorial Hospital, Lodz (T.R.), the Department of Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice (S.G.), and the Department of Hematology, University Clinical Center of Medical University of Gdansk, Gdansk (A.H.) - all in Poland; Tom Baker Cancer Centre, Calgary, AB, Canada (C.O.); Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv (O.B.), and Hadassah University Hospital, Hebrew University Medical School, Jerusalem (A.P.) - both in Israel; Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds (P.H.), Kings College Hospital, London (S.D.), Royal Bournemouth Hospital, Bournemouth (H.M.), and University of Oxford, Oxford (A.S.) - all in the United Kingdom; Washington University School of Medicine, St. Louis (N.L.B.); Jiangsu Province Hospital, Nanjing, China (J.L.); North Shore Hospital, Auckland, New Zealand (D. Simpson); Stanford University School of Medicine, Stanford (S.C.), City of Hope National Medical Center, Duarte (T.S.), Pharmacyclics, Sunnyvale (D. Suri, M.C., F.C., L.S., D.F.J.), and Moores Cancer Center, University of California, San Diego, San Diego (T.J.K.) - all in California; St. Vincent's Hospital, University of Melbourne (H.Q.), and Peter MacCallum Cancer Centre and St. Vincent's Hospital (C.S.T.), Melbourne, VIC, Australia; Institute of Blood Pathology and Transfusion Medicine, National Academy of Medical Sciences of Ukraine, Lviv, Ukraine (Z.M.); Norton Cancer Institute, Louisville, KY (D.A.S.);

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509388DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722809PMC
December 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

A pediatric case of T-cell prolymphocytic leukemia.

Pediatr Blood Cancer 2015 Jun 21;62(6):1061-2. Epub 2014 Nov 21.

Department of Pediatrics, Division of Hematology-Oncology and Stem Cell Transplantation, Lucile Packard Children's Hospital at Stanford University, Palo Alto, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.25336DOI Listing
June 2015

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

N Engl J Med 2014 Mar 22;370(11):997-1007. Epub 2014 Jan 22.

Weill Cornell Medical College (R.R.F.), Memorial Sloan-Kettering Cancer Center (A.D.Z.), the Department of Medicine, and Columbia University Medical Center (N.L.) - all in New York; U.S. Oncology Research, Springfield, OR (J.P.S.); Stanford University School of Medicine, Stanford (S.E.C.), and Gilead Sciences, Foster City (M.A., D.M.J., L.L.M., D.L., T.M.J., R.D.D.) - both in California; Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC (B.D.C.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (J.M.P.); St. James's University Hospital, Leeds (P.H.), and Royal Liverpool University Hospital, Liverpool (A.R.P.) - both in the United Kingdom; Hofstra North Shore-LIJ School of Medicine, New Hyde Park, New York (J.C.B.); University of California San Diego, Moores Cancer Center, La Jolla (T.J.K.); Sarah Cannon Research Institute, Nashville (I.F.); Universita Vita-Salute San Raffaele, Instituto Scientifico San Raffaele, Milan (P.G.); David Geffen School of Medicine, University of California Los Angeles, Los Angeles (H.E.); Florida Cancer Specialists, Englewood (T.E.); Centre Hospitalier Lyon-Sud, Pierre-Bénite, France (B.C.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (S.M.); University of Ulm, Ulm (S.S.), and University of Cologne, Cologne (P.C., M.H.) - both in Germany; and University of Texas M.D. Anderson Cancer Center, Houston (S.M.O.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1315226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365PMC
March 2014

Acute myeloid leukemia, version 2.2013.

J Natl Compr Canc Netw 2013 Sep;11(9):1047-55

From 1City of Hope Comprehensive Cancer Center; 2Memorial Sloan-Kettering Cancer Center; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 5Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 6Stanford Cancer Institute; 7Massachusetts General Hospital Cancer Center; 8University of Alabama at Birmingham Comprehensive Cancer Center; 9UCSF Helen Diller Family Comprehensive Cancer Center; 10Moffitt Cancer Center; 11UNMC Eppley Cancer Center at The Nebraska Medical Center; 12The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 13St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 14Fox Chase Cancer Center; 15Duke Cancer Institute; 16The University of Texas MD Anderson Cancer Center; 17Huntsman Cancer Institute at the University of Utah; 18The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 19Dana-Farber Cancer Institute; 20Vanderbilt-Ingram Cancer Center; 21Roswell Park Cancer Institute; and 22National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161234PMC
http://dx.doi.org/10.6004/jnccn.2013.0127DOI Listing
September 2013

Treatment advances have not improved the early death rate in acute promyelocytic leukemia.

Haematologica 2012 Jan 11;97(1):133-6. Epub 2011 Oct 11.

Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305-5821, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2011.046490DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248942PMC
January 2012

Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia.

Am J Hematol 2012 Jan 4;87(1):45-50. Epub 2011 Nov 4.

Department of Medicine, Division of Hematology, Stanford University School of Medicine, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.22191DOI Listing
January 2012

Classification and risk stratification for acute promyelocytic leukemia.

Authors:
Steven Coutre

Clin Lymphoma Myeloma Leuk 2010 Oct;10 Suppl 3:S127-9

Stanford University, 875 Blake Wilbur Dr., Stanford, CA 94305-5820, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLML.2010.s.024DOI Listing
October 2010

Optimizing therapy for acute myeloid leukemia.

J Natl Compr Canc Netw 2008 Nov;6(10):1003-16

Department of Medicine, Division of Hematology, Stanford University, Stanford, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2008.0076DOI Listing
November 2008

Myelodysplastic syndromes: disease overview and therapy options.

Authors:
Steven Coutré

Manag Care 2008 Jul;17(7 Suppl 6):3-8

Stanford University School of Medicine, Calif, USA.

View Article

Download full-text PDF

Source
July 2008

Acute postoperative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer.

Gynecol Oncol 2007 Aug 17;106(2):423-6. Epub 2007 May 17.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, 300 Pasteur Drive, HH333, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S009082580700260
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2007.04.005DOI Listing
August 2007

Von Willebrand disease presenting as recurrent hemorrhage after transvaginal oocyte retrieval.

Am J Obstet Gynecol 2007 Apr;196(4):e10-1

Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Stanford Hospital, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajog.2007.01.025DOI Listing
April 2007